Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02035982

NCT02035982
Completed Phase 3

Who may be able to join

Who might be able to join this trial:

  • You are older than 55 years of age
  • You have been diagnosed with Alzheimer's disease (a type of progressive memory and thinking condition) according to recognised medical guidelines
  • Your Alzheimer's diagnosis has been confirmed for at least one year
  • You have severe dementia, shown by a score of 15 or below on a standard memory and thinking test called the MMSE
  • You have been taking one of these Alzheimer's medications — donepezil, galantamine, or rivastigmine — for at least 2 years, and your dose has not changed for at least 3 months before joining the trial
  • If you take any regular medication for mood, anxiety, or behaviour (such as antidepressants or antipsychotics), your dose must have been stable for at least 1 month before joining the trial

Who may not be able to join:

  • You have dementia caused by something other than Alzheimer's disease
  • You have significant difficulty swallowing or taking tablets or capsules by mouth
  • You have a serious medical condition that is not well controlled and could affect your ability to take part in the study (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Sunnybrook Health Sciences Centre
Registry
clinicaltrials_gov
Start date
1 July 2010
Est. completion
1 May 2014

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Clinician's Global Impression of Change (CGIC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov